Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGG492 for prevention of non-chronic migraine
2011-005316-28Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in migraine comparing BGG492 BID with Placebo BID (2 arms). Primary endpoint: 50% responder rate. Started Mar 2012; status: terminated.
02
Drugs
selurampanel
03
Conditions
migraine
Beyond the preview
Go deeper on 2011-005316-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005316-28.